The Global Ankylosing Spondylitis Market Size accounted for USD 5.1 Billion in 2022 and is projected to achieve a market size of USD 9.5 Billion by 2032 growing at a CAGR of 6.5% from 2023 to 2032.
Ankylosing Spondylitis Market Highlights
- Global Ankylosing Spondylitis Market revenue is expected to increase by USD 9.5 Billion by 2032, with a 6.5% CAGR from 2023 to 2032
- North America region led with more than 43% of Ankylosing Spondylitis Market share in 2022
- Asia-Pacific Ankylosing Spondylitis Market growth will record a CAGR of around 7.1% from 2023 to 2032
- By treatment types, the medication is the largest segment of the market, accounting for over 62% of the global market share
- By end user, the hospital is one of the largest and fastest-growing segments of the ankylosing spondylitis industry
- Increasing prevalence and diagnosis of ankylosing spondylitis, drives the Ankylosing Spondylitis Market value
Ankylosing spondylitis (AS) is a chronic inflammatory autoimmune disease that primarily affects the spine and sacroiliac joints, causing pain, stiffness, and eventually leading to fusion of the affected joints. It falls under the category of spondyloarthritis, a group of related conditions that primarily target the axial skeleton. AS typically starts in early adulthood and progresses over time, often resulting in decreased mobility and a reduced quality of life for affected individuals. Symptoms may extend beyond the spine to involve other joints, eyes, and even organs in some cases.
In recent years, there has been significant interest and growth in the market for treatments and therapies related to ankylosing spondylitis. This growth can be attributed to several factors, including increased awareness and diagnosis of the condition, advancements in medical research and technology, and the development of innovative pharmaceuticals and biologics designed to manage the symptoms and slow down the progression of AS. Additionally, a growing aging population, who are more susceptible to autoimmune diseases like AS, has contributed to the expansion of this market. As the understanding of AS continues to evolve, it is likely that the market for AS-related treatments will continue to expand, offering hope for improved outcomes and better quality of life for individuals living with this challenging condition.
Global Ankylosing Spondylitis Market Trends
Market Drivers
- Increasing prevalence and diagnosis of ankylosing spondylitis
- Advancements in biologic therapies and treatment options
- Growing aging population susceptible to autoimmune diseases
- Expanding healthcare infrastructure and access to treatment
- Rising patient awareness and advocacy efforts
Market Restraints
- High cost of biologic medications and long-term treatment
- Stringent regulatory requirements for drug approval
Market Opportunities
- Development of personalized medicine approaches for AS
- Expansion of telemedicine and digital health solutions
Ankylosing Spondylitis Market Report Coverage
Market | Ankylosing Spondylitis Market |
Ankylosing Spondylitis MarketSize 2022 | USD 5.1 Billion |
Ankylosing Spondylitis MarketForecast2032 | USD 9.5 Billion |
Ankylosing Spondylitis MarketCAGR During 2023 - 2032 | 6.5% |
Ankylosing Spondylitis MarketAnalysis Period | 2020 - 2032 |
Ankylosing Spondylitis MarketBase Year | 2022 |
Ankylosing Spondylitis MarketForecast Data | 2023 - 2032 |
Segments Covered | By Treatment Types, By End User, And ByGeography |
Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
Key Companies Profiled | AbbVie Inc., Amgen Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Merck & Co., Inc., and GlaxoSmithKline plc (GSK) |
Report Coverage | Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Covid-19 Analysis, Regulation Analysis |
Ankylosing Spondylitis Market Dynamics
Ankylosing spondylitis (AS) is a chronic inflammatory autoimmune disease that primarily affects the axial skeleton, including the spine and sacroiliac joints. It is characterized by pain, stiffness, and eventual fusion of the affected joints. AS falls under the category of spondyloarthritis and typically manifests in early adulthood. Over time, the inflammation can lead to the formation of new bone, causing the spine to become rigid and less flexible. This can result in significant disability and a reduced quality of life for individuals with AS. Moreover, AS can extend beyond the axial skeleton to involve other joints, such as the hips and shoulders, and may even affect the eyes, heart, and other organs in some cases.
The applications related to ankylosing spondylitis are primarily in the field of healthcare and pharmaceuticals. Pharmaceutical companies and researchers are actively engaged in developing and testing new medications and therapies to manage the symptoms and slow down the progression of AS. These treatments aim to reduce pain, improve mobility, and enhance the overall well-being of patients. Additionally, advancements in diagnostic techniques and imaging technologies have improved the early detection of AS, allowing for timely intervention and treatment.
The market for ankylosing spondylitis (AS) treatments has been experiencing steady growth in recent years, driven by several key factors. One of the primary drivers is the increasing prevalence and diagnosis of AS. As healthcare systems and diagnostic capabilities improve, more individuals are being accurately identified and treated for AS, leading to a larger patient pool and higher demand for therapeutic options. Advancements in biological therapies and treatment options have also contributed significantly to market growth. These innovative medications have demonstrated effectiveness in managing AS symptoms and improving patients' quality of life. With ongoing research and development efforts, the pipeline for AS drugs continues to expand, offering new treatment options that are likely to fuel further market growth.
Ankylosing Spondylitis Market Segmentation
The global Ankylosing Spondylitis Market segmentation is based on treatment types, end user, and geography.
Ankylosing Spondylitis Market By Treatment Types
- Medication
- IL-17 Inhibitors
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- TNF Inhibitors
- Others
- Surgery
- Therapy
In terms of treatment types, the medication segment accounted for the largest market share in 2022. One of the most notable developments has been the emergence and widespread adoption of biologic therapies, such as tumor necrosis factor-alpha (TNF-alpha) inhibitors. These drugs have revolutionized the treatment landscape for AS, offering patients effective relief from pain and inflammation, as well as the potential to slow disease progression. The availability of biologics has expanded treatment options, leading to improved outcomes and enhanced patient quality of life. This growth in biologic therapies is expected to continue as research and development efforts focus on developing even more targeted and effective treatments for AS. Furthermore, the market for AS medications has seen the introduction of biosimilars, which are similar but not identical versions of existing biologics.
Ankylosing Spondylitis Market By End User
- Hospitals
- Clinics
- Ambulatory Surgery Centres
- Others
According to the ankylosing spondylitis market forecast, the hospitals segment is expected to witness significant growth in the coming years. The increasing prevalence of AS, coupled with the rising awareness and diagnosis rates, has led to a growing number of AS patients seeking medical care and treatment in hospitals. As the disease often requires long-term management, hospitals play a central role in providing specialized care and therapies to patients with AS. Moreover, the development of multidisciplinary AS clinics within hospitals has contributed to market growth. These specialized clinics bring together rheumatologists, orthopedic specialists, physical therapists, and other healthcare professionals to offer comprehensive and tailored treatment plans for AS patients. This approach not only improves patient outcomes but also enhances the reputation and competitiveness of hospitals in providing high-quality AS care.
Ankylosing Spondylitis Market Regional Outlook
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa
- South Africa
- GCC Countries
- Rest of the Middle East & Africa (ME&A)
Ankylosing Spondylitis Market Regional Analysis
Geographically, North America has emerged as a dominant region in the ankylosing spondylitis (AS) market in 2022. North America benefits from a well-established and advanced healthcare infrastructure. This includes a robust network of hospitals, clinics, and specialized treatment centers that offer comprehensive care to AS patients. The availability of skilled healthcare professionals, including rheumatologists and orthopedic specialists, ensures that patients receive timely and specialized care, contributing to better disease management and outcomes. Furthermore, North America has a relatively high prevalence of AS compared to other regions, which has driven both awareness and research efforts. The region's strong focus on medical research and innovation has led to the development of cutting-edge treatments and therapies for AS. Pharmaceutical companies in North America have been at the forefront of developing biologic medications and biosimilars, which have transformed the AS treatment landscape. These innovations have not only improved the quality of life for AS patients but have also made North America an attractive market for healthcare investments and clinical trials, further cementing its dominant position in the AS market.
Ankylosing Spondylitis Market Player
Some of the top ankylosing spondylitis market companies offered in the professional report include AbbVie Inc., Amgen Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Merck & Co., Inc., and GlaxoSmithKline plc (GSK).
CHAPTER 1. Industry Overview of Ankylosing Spondylitis Market
1.1. Definition and Scope
1.1.1. Definition of Ankylosing Spondylitis
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Ankylosing Spondylitis Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Ankylosing Spondylitis Market By Treatment Types
1.2.3. Ankylosing Spondylitis Market By End User
1.2.4. Ankylosing Spondylitis Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Source
2.2.2. Primary Source
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Ankylosing Spondylitis Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Ankylosing Spondylitis Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Price Trend of Key Raw Material
3.8.1. Raw Material Suppliers
3.8.2. Proportion of Manufacturing Cost Structure
3.8.2.1. Raw Material
3.8.2.2. Labor Cost
3.8.2.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2022
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2022
4.2. R&D Status of Major Manufacturers in 2022
CHAPTER 5. Ankylosing Spondylitis Market By Treatment Types
5.1. Introduction
5.2. Ankylosing Spondylitis Revenue By Treatment Types
5.2.1. Ankylosing Spondylitis Revenue (USD Billion) and Forecast, By Treatment Types, 2020-2032
5.2.2. Medication
5.2.2.1. Medication Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.2.2. IL-17 Inhibitors
5.2.2.2.1. IL-17 Inhibitors Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.2.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.2.2.3.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.2.4. TNF Inhibitors
5.2.2.4.1. TNF Inhibitors Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.2.5. Others
5.2.2.5.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. Surgery
5.2.3.1. SurgeryMarket Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.4. Therapy
5.2.4.1. TherapyMarket Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Ankylosing Spondylitis Market By End User
6.1. Introduction
6.2. Ankylosing Spondylitis Revenue By End User
6.2.1. Ankylosing Spondylitis Revenue (USD Billion) and Forecast, By End User, 2020-2032
6.2.2. Hospitals
6.2.2.1. Hospitals Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. Clinics
6.2.3.1. ClinicsMarket Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4. Ambulatory Surgery Centres
6.2.4.1. Ambulatory Surgery Centres Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.5. Others
6.2.5.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. North America Ankylosing Spondylitis Market By Country
7.1. North America Ankylosing Spondylitis Market Overview
7.2. U.S.
7.2.1. U.S. Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
7.2.2. U.S. Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
7.3. Canada
7.3.1. Canada Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
7.3.2. Canada Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
7.4. North America PEST Analysis
CHAPTER 8. Europe Ankylosing Spondylitis Market By Country
8.1. Europe Ankylosing Spondylitis Market Overview
8.2. U.K.
8.2.1. U.K. Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
8.2.2. U.K. Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
8.3. Germany
8.3.1. Germany Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
8.3.2. Germany Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
8.4. France
8.4.1. France Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
8.4.2. France Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
8.5. Spain
8.5.1. Spain Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
8.5.2. Spain Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
8.6. Rest of Europe
8.6.1. Rest of Europe Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
8.6.2. Rest of Europe Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Ankylosing Spondylitis Market By Country
9.1. Asia Pacific Ankylosing Spondylitis Market Overview
9.2. China
9.2.1. China Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
9.2.2. China Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
9.3. Japan
9.3.1. Japan Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
9.3.2. Japan Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
9.4. India
9.4.1. India Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
9.4.2. India Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
9.5. Australia
9.5.1. Australia Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
9.5.2. Australia Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
9.6. South Korea
9.6.1. South Korea Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
9.6.2. South Korea Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
9.7.2. Rest of Asia-Pacific Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Ankylosing Spondylitis Market By Country
10.1. Latin America Ankylosing Spondylitis Market Overview
10.2. Brazil
10.2.1. Brazil Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
10.2.2. Brazil Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
10.3. Mexico
10.3.1. Mexico Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
10.3.2. Mexico Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
10.4. Rest of Latin America
10.4.1. Rest of Latin America Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
10.4.2. Rest of Latin America Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
10.5. Latin America PEST Analysis
CHAPTER 11. Middle East & Africa Ankylosing Spondylitis Market By Country
11.1. Middle East & Africa Ankylosing Spondylitis Market Overview
11.2. GCC
11.2.1. GCC Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
11.2.2. GCC Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
11.3. South Africa
11.3.1. South Africa Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
11.3.2. South Africa Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Ankylosing Spondylitis Revenue (USD Billion) and Forecast By Treatment Types, 2020-2032
11.4.2. Rest of Middle East & Africa Ankylosing Spondylitis Revenue (USD Billion) and Forecast By End User, 2020-2032
11.5. Middle East & Africa PEST Analysis
CHAPTER 12. Player Analysis Of Ankylosing Spondylitis Market
12.1. Ankylosing Spondylitis Market Company Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking Of Key Players By Price, Presence, Market Share, And R&D Investment
12.2.2. New Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition In Global Ankylosing Spondylitis Market
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. Company Profile
13.1. AbbVie Inc.
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (USD Billion), 2022
13.1.3.2. AbbVie Inc. 2022 Ankylosing Spondylitis Business Regional Distribution
13.1.4. Product/Service and Specification
13.1.5. Recent Developments & Business Strategy
13.2. Amgen Inc.
13.3. Pfizer Inc.
13.4. Novartis AG
13.5. Eli Lilly and Company
13.6. Johnson & Johnson
13.7. UCB S.A.
13.8. Boehringer Ingelheim Pharmaceuticals, Inc.
13.9. Bristol Myers Squibb
13.10. Merck & Co., Inc.
13.11. GlaxoSmithKline plc (GSK)